89bio Presents Positive Results from Phase 2 Trial in Hypertriglyceridemia

 -Results featured in a late-breaking oral presentation-

-Treatment with pegozafermin demonstrated consistent and significant benefit in triglyceride (TG) reduction as well as improvements in liver fat and glycemic control-

-Positive data support the advancement into a Phase 3 trial in SHTG-

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the presentation of data from ENTRIGUE, its Phase 2 proof-of-concept trial of pegozafermin in severe hypertriglyceridemia (SHTG) at the European Society of Cardiology (ESC) Congress 2022. Deepak L. Bhatt, MD, MPH, Brigham and Women’s Hospital and Harvard Medical School, presented the data during the Late-Breaking Science Innovations in Drug Treatment session at the Congress, in Barcelona, Spain and virtually on August 26-29, 2022. A copy of the oral presentation will be accessible under “Scientific Publications” in the pipeline section of 89bio’s website.

https://finance.yahoo.com/news/89bio-presents-positive-results-entrigue-100000375.html